Author

Lisa M Tachiki

Observed names: L. Tachiki, Lisa ML Tachiki

Institution: Fred Hutch Cancer Center

Observed institutions: University of Washington, Fred Hutch Cancer Center

OpenAlex ID: A5074097438

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

2021 · Michael A. Thompson, Jeffrey P. Henderson, et al. · JAMA Oncology · 192

526 Pharmacokinetic and pharmacodynamic analyses of PD-1 blockade with nivolumab at varying doses and schedules supports administration at markedly reduced dose and frequency

2024 · Lisa M Tachiki, Haroldo Rodriguez Chevez, et al. · Regular and Young Investigator Award Abstracts · 2

292 Is it safe to discontinue immunotherapy after a response in merkel cell carcinoma?

2022 · L. Tachiki, L. Zawacki, et al. · Journal of Investigative Dermatology · 1

Clinical Outcomes of Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients with Advanced Cancers

2026 · G. Huang, D.S. Hippe, et al. · American Journal of Transplantation

608 A phase I clinical trial of a personalized neoantigen vaccine in PD-1 inhibitor refractory metastatic melanoma

2025 · Joshua Veatch, William Gwin, et al. · Regular and Young Investigator Award Abstracts

Works count: 5

Citation count: 195

H-index: 2

I10-index: 1